What Clobazam TioFarma Treats: Main Uses and Benefits

Clobazam TioFarma is commonly used to help with situations involving certain distressing symptoms related to heightened physiological activity. The medication plays a role in managing symptoms related to increased neurological or muscular activity and is relevant in conditions characterized by periods of heightened symptoms, such as Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older. This includes severe, recurrent seizure manifestations, such as atonic and tonic seizures, where supportive symptom management is appropriate.

The medication is also relevant for easing symptoms related to physical discomfort, such as those associated with anxiety and chronic agitation. It is applied across domains where additional symptomatic support is needed for managing certain distressing symptoms. This use provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability and contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Intractable Seizures and Agitation

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications

Official regulatory documents define strict criteria for the use of this medicine, establishing specific patient groups who must not take it (contraindications) and those for whom use is limited or requires special consideration.

Exclusion Criteria (Must Not Use)	Official Status
Hypersensitivity to clobazam, other benzodiazepines, or excipients	Contraindicated
Myasthenia gravis	Contraindicated
Severe respiratory insufficiency or sleep apnoea syndrome	Contraindicated
Severe impairment of liver function	Contraindicated
History of drug or alcohol dependence	Contraindicated
Narrow-angle glaucoma	Contraindicated (in some jurisdictions)

For the pediatric population, use is not established for children younger than two years of age. In specific jurisdictions, use in children between six months and three years is generally prohibited except in exceptional cases for anticonvulsant treatment. Pregnant women and breastfeeding mothers should not use the medicine, as documented in official labeling on pregnancy and lactation eligibility status. Use in elderly patients is generally not recommended for long-term treatment, and efficacy has not been established in this age group.

The official regulatory profile for Clobazam TioFarma details several interactions that require specific restrictions. A primary constraint is the additive central nervous system (CNS) depressant effect documented to occur with co-administration. This is noted for substance categories including opioids, antipsychotics, narcotic analgesics, and other CNS depressants. Due to this risk, concurrent use with these agents may lead to increased sedation and respiratory depression.

Acute alcohol intoxication is a formally contraindicated combination as alcohol significantly increases Clobazam's bioavailability. A key pharmacokinetic interaction involves the active metabolite, N-desmethylclobazam (N-CLB). Co-administration with strong or moderate CYP2C19 inhibitors, such as fluconazole or fluvoxamine, is documented to result in significantly increased N-CLB exposure.

Conversely, Clobazam itself is classified as a weak inhibitor of CYP2D6, which may require consideration for the clearance of co-administered CYP2D6 substrate medicines. Cannabidiol (CBD) is also documented to cause a substantial increase in the systemic exposure of N-CLB.

Furthermore, Clobazam is known to reduce the effectiveness of systemic hormonal contraceptives, creating an official restriction that mandates the use of nonhormonal barrier methods during and following treatment. Population-specific considerations regarding interaction effects are noted for CYP2C19 Poor Metabolizers and patients with hepatic impairment, as these groups exhibit higher plasma exposure.

Clobazam and its principal active metabolite, N-desmethylclobazam (norclobazam), are lipophilic compounds that readily cross the blood-brain barrier to target the central nervous system (CNS). Their primary biological target is the GABAA receptor, a ligand-gated chloride ion channel. Clobazam acts as a positive allosteric modulator at the benzodiazepine binding site, which is located at the interface of the alpha and gamma subunits, particularly those containing alpha1, alpha2, alpha3, and alpha5 subunits.

Upon binding, clobazam induces a conformational change in the receptor complex. This allosteric modification does not activate the channel directly but enhances the affinity of the endogenous inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), for its binding site. The augmented GABA-mediated signal increases the frequency of chloride channel opening. The subsequent influx of negatively charged chloride ions (Cl^-) across the neuronal membrane causes a hyperpolarization of the postsynaptic neuron. This change shifts the neuronal membrane potential further away from the threshold required for action potential generation, thereby diminishing overall neuronal excitability. The system-level physiological consequence is a widespread modulation of inhibitory neurotransmission throughout the CNS.

How to use Clobazam TioFarma

Clobazam is administered orally, with or without food, as directed by a healthcare provider.

Dosing and Schedule

Daily doses greater than 5 mg are typically administered in two divided doses (e.g., twice daily); a 5 mg daily dose can be given as a single dose. Dosing is individualized and depends on the patient's body weight (30 kg or less or > 30 kg). The total daily dose is gradually increased (titrated) over time. Dose escalation should not proceed more rapidly than weekly to allow steady-state concentrations to be reached.

Special Population Dosing: A lower initial dose (e.g., 5 mg daily) and slower titration (often to half the standard maximum dose) are required for elderly patients, those with mild to moderate hepatic impairment, and individuals known to be CYP2C19 poor metabolizers.

Administration Method by Formulation

Formulation	Administration Instruction (Official)
Tablet	Can be swallowed whole, broken in half along the score, or crushed and mixed with applesauce or other soft food.
Oral Suspension	Shake the bottle well before every administration. Use only the provided oral dosing syringe to measure the prescribed amount.
Oral Film	Place on the top of the tongue and allow it to dissolve completely. Do not chew, spit, or take with liquids while the film is dissolving.

Other Instructions

If a dose is missed, take it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not double doses. Treatment must be discontinued gradually. The official instruction for gradual withdrawal is to taper by decreasing the total daily dose by 5-10 mg/day on a weekly basis until discontinued.

The research on Clobazam TioFarma was studied for its use primarily in two clinical contexts: as an add-on treatment for a specific form of childhood epilepsy, and historically, for managing symptoms related to anxiety. The available evidence contributes to the broader evidence landscape.

---

Evidence for use in Lennox-Gastaut Syndrome (LGS)

Research was evaluated in short-term, randomized, double-blind, placebo-controlled Phase III trials involving pediatric and young adult patients with LGS who were already receiving other medications (adjunctive setting). The main focus of the research examined outcomes describing episodic or acute changes, specifically assessing the percentage change in the mean weekly frequency of drop seizures. Studies reported measurements of change in weekly drop seizure rates in the dosage groups examined. Open-label follow-up studies research describes that for the group of patients followed, a pattern of sustained outcomes was observed in some studies over the first three years of use.

---

Research Context for Anxiolytic and Agitation Symptoms

The clinical research history includes short-term randomized controlled trials that were studied for outcomes related to systemic imbalance, often comparing the compound against placebo or an active comparator. Findings describe patterns observed in these older studies which supported the medicine’s general pharmacological classification. Evidence quality varies across these trials, and this evidence is generally supportive, but not the primary regulatory focus in major markets.

---

What is Still Uncertain About the Research Evidence

The core evidence for LGS is structured around adjunctive use, meaning comparative evidence is lacking for its use as a single-agent treatment. The follow-up durations for the primary, controlled findings were limited (e.g., 12 weeks). Data for certain groups, such as older adults, remain insufficient, and research has not formally studied how Clobazam TioFarma may influence coexisting conditions like behavioral challenges.

Key Studies & References

1. Australian public assessment report for Clobazam (Historical context and regulatory approval for LGS)
2. Clobazam - LiverTox - NCBI Bookshelf (Review on hepatotoxicity and general use context)

Common questions about Clobazam TioFarma (FAQ)

Q: Does Clobazam TioFarma treat a condition or only help manage symptoms?

Clobazam is officially indicated as adjunctive treatment, meaning it is used alongside other medications. Its purpose is to help manage and reduce the frequency of seizures associated with a specific form of epilepsy called Lennox-Gastaut syndrome (LGS).

Q: How does the mechanism of action differ from non-benzodiazepine seizure medications?

Clobazam is a specific type of drug called a 1,5-benzodiazepine. It works by enhancing the calming effects of the brain's main inhibitory chemical, GABA, at the GABAA receptor. This pharmacological action, which involves modulating this specific receptor, is generally distinct from how many other non-benzodiazepine seizure medications function.

Q: Is there a connection between Clobazam TioFarma and changes in appetite or weight?

Official regulatory documents list increased appetite as a less common side effect associated with Clobazam use. Changes in weight are possible, though less commonly reported.

Q: How often is headache reported as a side effect of Clobazam TioFarma?

Headache is listed as a possible side effect in the official product information. However, regulatory documents do not categorize it as a 'common' or 'very common' adverse reaction.

Q: What type of vision changes are associated with Clobazam TioFarma use?

Official regulatory documents indicate that potential vision changes can include blurred vision and double vision (diplopia). These effects are typically noted in the adverse reaction tables.

Q: What are the signs of a hypersensitivity or allergic reaction to Clobazam TioFarma?

Clobazam carries a risk of severe skin reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome (SJS). The labeling describes severe reactions where signs may include a rash along with fever, swollen glands, or potential injury to internal organs.

Q: Does Clobazam TioFarma have potential side effects on the liver or kidneys?

The medicine is generally contraindicated (not to be used) in people with severe liver function impairment. Additionally, the rare but serious DRESS reaction mentioned in the safety information is documented to potentially cause injury to the liver or kidneys.

Q: Does Clobazam TioFarma interfere with blood tests or other laboratory markers?

Blood tests are often used by healthcare providers to measure the levels of Clobazam and its active metabolite in the body. This monitoring helps assess the levels of the medicine in the body to help inform treatment.

Q: Are herbal supplements or complementary medicines known to interact with Clobazam TioFarma?

Regulatory information specifically warns about co-administration with Cannabidiol (CBD). Studies have shown that CBD can cause a substantial increase in the systemic exposure of the active metabolite, norclobazam.

Q: How does Clobazam TioFarma affect the body's metabolism of other drugs?

Official information classifies Clobazam as a weak inhibitor of CYP2D6, which is a type of enzyme in the body responsible for processing many medications. This may be a factor to consider for the clearance of other co-administered medicines that are processed by that enzyme.

Q: Is there a warning about using Clobazam TioFarma with cannabis (marijuana) products?

Using Clobazam with cannabis products may increase central nervous system (CNS) depressant effects, according to official warnings about CNS depressants. This can lead to increased feelings of dizziness, drowsiness, confusion, and difficulty concentrating.

Q: Is it possible for Clobazam TioFarma to lose effectiveness over time (tolerance)?

Tolerance, or the gradual loss of effectiveness over time, has been reported with Clobazam in some studies. However, available research generally suggests that tolerance is not a frequently reported problem for many patients.

Q: What physical symptoms are associated with Clobazam TioFarma withdrawal?

Withdrawal symptoms reported following abrupt discontinuation of benzodiazepines include severe effects such as convulsions, psychosis, hallucinations, behavioral disorder, and tremor.

Q: Are there specific factors that increase the risk of dependence on Clobazam TioFarma?

Official product information notes that patients with a history of substance abuse are officially noted to warrant careful monitoring for signs of habituation and dependence.

Q: What is the time frame for withdrawal symptoms after stopping Clobazam TioFarma?

Withdrawal symptoms have been reported following the abrupt discontinuance of benzodiazepines taken continuously for several months. Because the active metabolite stays in the body for some time, withdrawal symptoms typically appear later than with some other benzodiazepines.

Q: Can sudden stopping of Clobazam TioFarma lead to status epilepticus?

Official warnings state that, as with all antiepileptic drugs, Clobazam should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus (prolonged or recurrent seizure activity).

Q: What is the general risk level of misuse associated with Clobazam TioFarma?

Clobazam is a benzodiazepine, and its official labeling includes a Boxed Warning that highlights the risks of Abuse, Misuse, and Addiction. A Boxed Warning is a required regulatory caution, highlighting the seriousness of these risks.

Q: How does Clobazam TioFarma compare to other benzodiazepines used for seizures in terms of side effects?

Research suggests Clobazam has a unique chemical structure compared to some other medicines in its class. This structural difference is noted in research, which suggests it may have a different profile regarding sedation compared to some other benzodiazepines.

Q: Is there scientific research available about Clobazam TioFarma's effectiveness in patients who have tried many other treatments?

Yes. Clinical research, including studies on patients with drug-refractory epilepsy (epilepsy resistant to multiple prior treatments), has shown that Clobazam is effective as an adjunctive therapy in this population.

Storage and Disposal of Clobazam TioFarma

Official regulatory documents define specific requirements for storing and disposing of Clobazam.

---

Storage Conditions

Clobazam tablets must not be stored above 25 C. The oral suspension requires controlled room temperature, 20 C to 25 C (68 F to 77 F). Both formulations must be kept from freezing and stored away from excessive heat and moisture. The oral suspension must be stored in its original bottle, in an upright position, and the cap replaced securely after each use. All medicine must be kept out of the reach of children.

---

Stability and Disposal

The oral suspension must be used within 90 days of first opening the bottle. Any remaining product after this 90-day period must be safely discarded. Disposal of all unused or expired Clobazam must be completed in accordance with local requirements for medicinal waste.